Key Takeaway: The presentation titled 'Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease' was delivered by Dr. Pam R. Taub at the American Society for Preventive Cardiology Congress on July 31, 2026. This research highlights the prevalence of hypercortisolism in patients facing resistant hypertension and cardiovascular issues, suggesting important clinical implications.
Price reaction · baseline $114.49 (2026-07-31 close) · hit after-hours · clean, no other CORT news in the window
day 0 close · peak
-1.5%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation at a notable congress indicates recognition of the research.
Focus on a significant health issue like resistant hypertension.
Potential implications for cardiovascular disease management.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
12.9%
average across 6 past catalysts
Lead asset
CORT118335
Phase 1 · Antipsychotic-induced Weight Gain
Full Press Release Details
Presented : American Society for Preventive Cardiology ( ASPC ) 2026 Congress on CVD Prevention, 31 July 2026, Scottsdale , AZ
Presenter : Pam R. Taub , MD
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease appeared first on Corcept Therapeutics .
Frequently Asked Questions
What was the focus of the presentation?
The presentation focused on the prevalence of hypercortisolism in individuals with resistant hypertension and cardiovascular disease.
Who presented the research at the congress?
Dr. Pam R. Taub presented the research at the American Society for Preventive Cardiology Congress.